theres no business like poh business, page-13

Jack, Jeeper - How was the Golf & surf...you guys are living the dream....beats driving the desk all day.

Tarli- your locked in for 50 (nice number.... and we welcome punters to this thread regardless of gender, race, religion, age or political persasion)

and NT, Oscar & Saqqhara- no more songs ...for now.... however I reserve the right to inflict some more mischief while jiving in my boxers to Neil Diamond (LOL) after some future POH milestone ...or visit to the cellar

My thoughts on the week ahead? While we have no idea when our expected anns will hit- POH ALWAYS surprises with left of field results from the clinic- it must be a very busy Lab captained by the very able ( and attractive) Dr Ogru- given Esra has not released anything since the Diclofenac Study in Feb- I reckon there will be more news from her out tray which will nicely bolster the expected commercial side.

I feel we really do need some news flow now to sustain our current rally. Something like an update on the patch development (which Andrew Vizard infers is a done deal in his Annual Report) ooorrrr something like our APA01 which we have not heard anything on since Jan08 for example. This was a pre-clinical study demonstrating that the combination of POHs APA-01 product candidate and the statin atorvastatin (Lipitor™) significantly reduced serum lipids and inflammatory proteins involved in the development of atherosclerosis.

It is one of the sleeper clinical studies we dont read much on and yet it is of huge commercial importance and would be a blockbuster for a Global Pharma. POH's APA-01 profuct addresses an unmet and rapildy growing need worth many Billions to big Pharma- some further background informtn below if you are interested.

Dr Ogrus notes in Jan 2008:
Atorvastatin is the world’s largest selling drug with sales of US$13.6 billion annually and is the major contributor to the US$35.2 billion market for statin drugs globally.

“In particular there is an unmet need for a more effective treatment for elevated triglycerides and APA-01 has demonstrated efficacy in this area in this pre-clinical study.

“We are now assessing the impact of these results before determining our future strategy. However, the insulin, oxycodone and Phospha E® clinical programs will remain our priority for this year,”


From further from POH website:
Atherosclerosis, or the build-up of fatty deposits (plaques) on interior blood vessel walls, is a progressive process initially involving endothelial dysfunction and accumulation of lipids on the linings of blood vessel. Atherosclerotic lesions develop as a result of inflammatory stimuli, subsequent release of various cytokines, proliferation of smooth muscle cells, synthesis of connective tissue matrix, and accumulation of macrophages and lipids. Atherosclerosis is involved in the development of coronary heart disease, myocardial infarction, and stroke, among other diseases.